Sou Hu Cai Jing·2026-04-01 09:16Group 1 - The core viewpoint of the report indicates that Shanghai Pharmaceuticals (02607.HK) experienced a 3% year-on-year increase in total revenue, reaching 284 billion RMB, while net profit rose by 25.7% to 5.72 billion RMB [1] - The recurring net profit saw a decline of 26.7% year-on-year, amounting to 2.98 billion RMB, which is generally in line with expectations [1] - The earnings forecast for Shanghai Pharmaceuticals for 2026 to 2028 has been adjusted downwards by 1% to an increase of 3%, with the target price raised from 15 HKD to 15.2 HKD, maintaining a "Buy" rating [1] Group 2 - As of April 1, 2026, Shanghai Pharmaceuticals (02607.HK) closed at 11.67 HKD, reflecting a 1.04% increase, with a trading volume of 3.4077 million shares and a turnover of 39.8907 million HKD [1] - The stock has low attention from investment banks, with no ratings given in the past 90 days [1] - Shanghai Pharmaceuticals has a market capitalization of 10.615 billion HKD, ranking second in the pharmaceutical commercial II industry [1]